New vaccine targets tough ovarian cancer in tiny trial
NCT ID NCT07455071
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a personalized vaccine (YS247) made from a patient's own immune cells to fight a specific type of ovarian cancer (HRD-negative). Only 9 women who haven't been cured by standard therapy will take part. The main goal is to check safety, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized dendritic cell vaccine (YS247)
- What this could lead to
- If it works, this could point toward a new treatment option for a hard-to-treat form of ovarian cancer.
- What could go wrong
- This is a very early, small trial (9 people) focused on safety, not effectiveness. The vaccine is personalized and complex, so it may not work for everyone or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HRD-NEGATIVE EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.